

Francesco Sica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5867973/publications.pdf>

Version: 2024-02-01

11
papers

520
citations

1039880

9
h-index

1281743

11
g-index

11
all docs

11
docs citations

11
times ranked

1037
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity worsens central inflammation and disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1237-1246.	1.4	72
2	Practice-dependent motor cortex plasticity is reduced in non-disabled multiple sclerosis patients. <i>Clinical Neurophysiology</i> , 2020, 131, 566-573.	0.7	13
3	Interleukin-6 Disrupts Synaptic Plasticity and Impairs Tissue Damage Compensation in Multiple Sclerosis. <i>Neurorehabilitation and Neural Repair</i> , 2019, 33, 825-835.	1.4	26
4	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101430.	0.9	23
5	Fingolimod Immune Effects Beyond Its Sequestration Ability. <i>Neurology and Therapy</i> , 2019, 8, 231-240.	1.4	22
6	Fingolimod reduces the clinical expression of active demyelinating lesions in MS. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 215-219.	0.9	5
7	Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. <i>Journal of Neurology</i> , 2018, 265, 828-835.	1.8	45
8	Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1498.	4.5	262
9	Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism?. <i>Neurochemistry International</i> , 2014, 79, 44-56.	1.9	31
10	Electroencephalography and Dementia: A Literature Review and Future Perspectives. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 512-519.	0.8	6
11	Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer's Disease?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 525-528.	0.8	15